Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment
- PMID: 30933266
- DOI: 10.1093/cid/ciz074
Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment
Abstract
Two new drugs, delamanid and bedaquiline, have recently been approved for treatment of multidrug-resistant and extensively drug-resistant (XDR) tuberculosis. Here, we report a case of clofazimine, bedaquiline, and low-level delamanid resistances acquired during treatment of a patient with XDR tuberculosis.
Keywords: XDR-tuberculosis; bedaquiline resistance; delamanid resistance.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Comment in
-
Acquired Drug Resistance: Recognizing the Potential of Repurposed Drugs.Clin Infect Dis. 2019 Nov 13;69(11):2038-2039. doi: 10.1093/cid/ciz334. Clin Infect Dis. 2019. PMID: 31125392 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
